Erratum to Transforming growth factor-β induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes in human trabecular meshwork cells (Invest Ophthalmol Vis Sci (2011), 52, (5240-5250), 10.1167/iovs.11-7287);Transforming growth factor-β induces extracellular matrix protein Cross-linking lysyl oxidase (LOX) genes in human trabecular meshwork cells

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 8, 2011, Pages 5240-5250

  Sethi, Anirudh ^a   Mao, Weiming ^a   Wordinger, Robert J ^a   Clark, Abbot F ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN LYSINE 6 OXIDASE; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; SCLEROPROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; CROSS LINKING REAGENT; ISOENZYME; ISOPROTEIN; LOXL1 PROTEIN, HUMAN; OXIDOREDUCTASE; RECOMBINANT PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

AQUEOUS HUMOR OUTFLOW; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAOCULAR PRESSURE; LYSYL OXIDASE GENE; LYSYL OXIDASE LIKE 1 GENE; LYSYL OXIDASE LIKE 2 GENE; LYSYL OXIDASE LIKE 3 GENE; LYSYL OXIDASE LIKE 4 GENE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK; WESTERN BLOTTING; CELL CULTURE; CYTOLOGY; ENZYME INDUCTION; METABOLISM; OSMOLARITY; PHYSIOLOGY; TIME;

AMINO ACID OXIDOREDUCTASES; CELLS, CULTURED; CROSS-LINKING REAGENTS; ENZYME INDUCTION; EXTRACELLULAR MATRIX PROTEINS; HUMANS; ISOENZYMES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; OSMOLAR CONCENTRATION; PROTEIN ISOFORMS; PROTEIN-LYSINE 6-OXIDASE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TIME FACTORS; TRABECULAR MESHWORK; TRANSCRIPTION FACTOR AP-1; TRANSFORMING GROWTH FACTOR BETA;

EID: 80052616166     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7287a     Document Type: Erratum

References (49)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
2. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711-1720.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713, discussion 829-730.
4. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
5. Lütjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp Eye Res. 2005;81:1-4.
6. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727.
7. Inatani M, Tanihara H, Katsuta H, Honjo M, Kido N, Honda Y. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol. 2001;239: 109-113.
8. Picht G, Welge-Luessen U, Grehn F, Lütjen-Drecoll E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol. 2001;239:199-207.
9. Wordinger RJ, Clark AF, Agarwal R, et al. Cultured human trabecular meshwork cells express functional growth factor receptors. Invest Ophthalmol Vis Sci. 1998;39:1575-1589.
10. Bachmann B, Birke M, Kook D, Eichhorn M, Lütjen-Drecoll E. Ultrastructural and biochemical evaluation of the porcine anterior chamber perfusion model. Invest Ophthalmol Vis Sci. 2006;47: 2011-2020.
11. Fleenor DL, Shepard AR, Hellberg PE, Jacobson N, Pang IH, Clark AF. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest Ophthalmol Vis Sci. 2006;47:226-234.
12. Gottanka J, Chan D, Eichhorn M, Lütjen-Drecoll E, Ethier CR. Effects of TGF-beta2 in perfused human eyes. Invest Ophthalmol Vis Sci. 2004;45:153-158.
13. Shepard AR, Millar JC, Pang IH, Jacobson N, Wang WH, Clark AF. Adenoviral gene transfer of active human transforming growth factor-β2 elevates intraocular pressure and reduces outflow facility in rodent eyes. Invest Ophthalmol Vis Sci. 2010;51:2067-2076.
14. Schlotzer-Schrehardt U, Zenkel M, Kuchle M, Sakai LY, Naumann GO. Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res. 2001;73:765-780.
15. Fuchshofer R, Tamm ER. Modulation of extracellular matrix turnover in the trabecular meshwork. Exp Eye Res. 2009;88:683-688.
16. Welge-Lussen U, May CA, Lütjen-Drecoll E. Induction of tissue transglutaminase in the trabecular meshwork by TGF-β1 and TGF-β2. Invest Ophthalmol Vis Sci. 2000;41:2229-2238.
17. Babizhayev MA, Brodskaya MW. Immunohistochemical monitoring of the effect of a synthetic fibronectin-like peptide (Arg-Gly-Asp) on the age-related changes in the isolated human corneoscleral tissue of glaucomatous eyes. Mech Ageing Dev. 1993;72:1-12.
18. Lütjen-Drecoll E, Rittig M, Rauterberg J, Jander R, Mollenhauer J. Immunomicroscopical study of type VI collagen in the trabecular meshwork of normal and glaucomatous eyes. Exp Eye Res. 1989;48:139-147.
19. Dan J, Belyea D, Gertner G, Leshem I, Lusky M, Miskin R. Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma. Arch Ophthalmol. 2005;123:220-224.
20. Tovar-Vidales T, Roque R, Clark AF, Wordinger RJ. Tissue transglutaminase expression and activity in normal and glaucomatous human trabecular meshwork cells and tissues. Invest Ophthalmol Vis Sci. 2008;49:622-628.
21. Maki JM. Lysyl oxidases in mammalian development and certain pathological conditions. Histol Histopathol. 2009;24:651-660.
22. Rodriguez C, Rodriguez-Sinovas A, Martinez-Gonzalez J. Lysyl oxidase as a potential therapeutic target. Drug News Perspect. 2008;21:218-224.
23. Lopez B, Gonzalez A, Hermida N, Valencia F, de Teresa E, Diez J. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol. 2010;299:H1-H9.
24. Vadasz Z, Kessler O, Akiri G, et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol. 2005;43:499-507.
25. Akiri G, Sabo E, Dafni H, et al. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Res. 2003;63:1657-1666.
26. Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science. 2007;317:1397-1400.
27. Schlotzer-Schrehardt U. Molecular pathology of pseudoexfoliation syndrome/glaucoma: new insights from LOXL1 gene associations. Exp Eye Res. 2009;88:776-785.
28. Kobayashi T, Liu X, Wen FQ, et al. Smad3 mediates TGF-beta1 induction of VEGF production in lung fibroblasts. Biochem Biophys Res Commun. 2005;327:393-398.
29. Zode GS, Clark AF, Wordinger RJ. Bone morphogenetic protein 4 inhibits TGF-beta2 stimulation of extracellular matrix proteins in optic nerve head cells: role of gremlin in ECM modulation. Glia. 2009;57:755-766.
30. Wordinger RJ, Fleenor DL, Hellberg PE, et al. Effects of TGFbeta2, BMP-4, and gremlin in the trabecular meshwork: implications for glaucoma. Invest Ophthalmol Vis Sci. 2007;48: 1191-1200.
31. Laping NJ, Grygielko E, Mathur A, et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol. 2002;62:58-64.
32. Sawyer JS, Anderson BD, Beight DW, et al. Synthesis and activity of new aryl-and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem. 2003;46:3953-3956.
33. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol. 2007;22(suppl 1): S79-S84.
34. Omori S, Kitagawa H, Koike J, et al. Activated extracellular signalregulated kinase correlates with cyst formation and transforming growth factor-beta expression in fetal obstructive uropathy. Kidney Int. 2008;73:1031-1037.
35. Tsukada S, Westwick JK, Ikejima K, Sato N, Rippe RA. SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J Biol Chem. 2005;280:10055-10064.
36. Wrighton KH, Lin X, Feng XH. Phospho-control of TGF-beta superfamily signaling. Cell Res. 2009;19:8-20.
37. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415-424.
38. Liton PB, Li G, Luna C, Gonzalez P, Epstein DL. Cross-talk between TGF-beta1 and IL-6 in human trabecular meshwork cells. Mol Vis. 2009;15:326-334.
39. O'Neill LA, Greene C. Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol. 1998;63:650-657.
40. Hall MC, Young DA, Waters JG, et al. The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J Biol Chem. 2003;278:10304-10313.
41. Li JJ, Dong Z, Dawson MI, Colburn NH. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res. 1996;56:483-489.
42. Narayanan AS, Siegel RC, Martin GR. On the inhibition of lysyl oxidase by aminopropionitrile. Biochem Biophys Res Commun. 1972;46:745-751.
43. Saad FA, Torres M, Wang H, Graham L. Intracellular lysyl oxidase: effect of a specific inhibitor on nuclear mass in proliferating cells. Biochem Biophys Res Commun. 2010;396:944-949.
44. Lütjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW. Quantitative analysis of 'plaque material' in the inner-and outer wall of Schlemm's canal in normal-and glaucomatous eyes. Exp Eye Res. 1986;42:443-455.
45. Tektas OY, Lütjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res. 2009;88: 769-775.
46. Last JA, Pan T, Ding Y, et al. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci. 2011;52:2147-2152.
47. Ritch R, Schlotzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45:265-315.
48. Thomassin L, Werneck CC, Broekelmann TJ, et al. The proregions of lysyl oxidase and lysyl oxidase-like 1 are required for deposition onto elastic fibers. J Biol Chem. 2005;280:42848-42855.
49. Liu X, Zhao Y, Gao J, et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat Genet. 2004;36:178-182.